News
GSK secures European nod for easier-to-use Shingrix prefilled syringe
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
- By IPP Bureau
| January 09, 2026
Global biopharma powerhouse GSK has announced that the European Commission has approved a new prefilled syringe version of its shingles vaccine, Shingrix.
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration. The new prefilled syringe eliminates this step, streamlining the vaccination process.
“This new presentation of Shingrix has been designed to improve ease of administration, helping healthcare professionals to provide protection against shingles,” said Tony Wood, Chief Scientific Officer, GSK.
“Shingles is a painful disease that can have serious and long-lasting complications. It affects millions of people each year in Europe, often imposing a greater burden on people living with common chronic diseases such as cardiovascular disease and diabetes. GSK is proud to support the healthcare community by making administration of its shingles vaccine easier."
The approval follows data confirming that the prefilled syringe is technically comparable to the existing two-vial presentation. Importantly, the change does not alter the vaccine’s indication or dosing.
